|Day's Range||25.710 - 26.690|
|52 Week Range||19.960 - 26.690|
|PE Ratio (TTM)||40.27|
|Dividend & Yield||0.78 (3.06%)|
|1y Target Est||N/A|
Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.
Waltham-based Tesaro is capitalizing on the early success of its new cancer drug, handing over some development and commercial rights to Takeda in a deal worth up to $340 million plus royalties. Tesaro (TSRO) said Thursday that the once-daily pill, which is marketed in the U.S. as Zejula following an FDA approval in March, will be developed and sold by Takeda in Japan, where the drug giant is headquartered. Under the deal, Takeda will get development and commercial rights in four additional countries — South Korea, Taiwan, Russia and Australia — for all kinds of tumors except prostate cancer.
Japan's Nikkei share average fell to a more than one-week low on Tuesday morning after cyclical stocks lost ground as a stronger yen hit sentiment, while Toshiba Corp rallied after news a U.S. hedge fund ...